|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113523 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-01 08:33:35 |
|
注册时间: Date of Registration: |
2025-12-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
大学生普适性多模块健康教育网络平台的开发与验证——以HIV/AIDS防控为例 |
|
Public title: |
Development and Validation of a Universal Multi-Module Health Education Web Platform for University Students: A Randomized Controlled Trial of HIV/AIDS Prevention |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
大学生普适性多模块健康教育网页平台的开发与验证:以HIV/AIDS防控为例的一项随机对照试验 |
|
Scientific title: |
Development and Validation of a Universal Multi-Module Health Education Web Platform for University Students: A Randomized Controlled Trial of HIV/AIDS Prevention |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘桄男 |
研究负责人: |
绳宇 |
|
Applicant: |
Liu Guangnan |
Study leader: |
Sheng Yu |
|
申请注册联系人电话: Applicant telephone: |
+86 135 5445 0700 |
研究负责人电话: Study leader's telephone: |
+86 138 1069 1298 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lgn13554450700@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shengyumm@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市石景山区八大处路33号院北京协和医学院护理学院 |
研究负责人通讯地址: |
北京市石景山区八大处路33号院北京协和医学院护理学院 |
|
Applicant address: |
No 33 Ba Da Chu Road, Shijingshan District, Beijing, 100144 People’s Republic of China |
Study leader's address: |
No 33 Ba Da Chu Road, Shijingshan District, Beijing, 100144 People’s Republic of China |
|
申请注册联系人邮政编码: Applicant postcode: |
100144 |
研究负责人邮政编码: Study leader's postcode: |
100144 |
|
申请人所在单位: |
北京协和医学院护理学院 |
||
|
Applicant's institution: |
School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College |
||
|
研究负责人所在单位: |
北京协和医学院护理学院 |
||
|
Affiliation of the Leader: |
School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PUMCSON-2025-54 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京协和医学院护理学院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of the School of Nursing, Peking Union Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-22 00:00:00 |
||
|
伦理委员会联系人: |
李峥 |
||
|
Contact Name of the ethic committee: |
Zheng Li |
||
|
伦理委员会联系地址: |
北京市石景山区八大处路33号院北京协和医学院护理学院 |
||
|
Contact Address of the ethic committee: |
School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College No 33 Ba Da Chu Road, Shijingshan District, Beijing, 100144 People’s Republic of China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 135 5445 0700 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
lgn13554450700@163.com |
|
研究实施负责(组长)单位: |
中国医学科学院北京协和医学院护理学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市石景山区八大处路33号院北京协和医学院护理学院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No 33 Ba Da Chu Road, Shijingshan District, Beijing, 100144 People’s Republic of China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京协和医学院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Peking Union Medical College |
||||||||||||||||||||||
|
Target disease: |
Acquired Immune Deficiency Syndrome, AIDS |
||||||||||||||||||||||
|
Target disease code: |
1C62 |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 开发并建立大学生普适性多模块健康教育网页平台 2. 以大学生HIV/AIDS防控为例,命名平台的该部分为“防艾为爱”,通过该部分去验证网页平台模块教育功能效果 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To develop and establish a universal multi-module health education web platform tailored for university students. 2. To validate the educational efficacy of the platform’s modular design through a dedicated HIV/AIDS prevention section, titled "For Love, Against AIDS," as a representative case. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经普通高等学校招生全国统一考试入学,且目前就读于北京市高校的大学本科在读学生; 2.具有正常读写能力,可独立完成问卷填写; 3.签署知情同意书(详见附件2),自愿参与,能积极配合者; |
||||||||||||||||||||||
|
Inclusion criteria |
1. students enrolled through the national college entrance examination and currently attending undergraduate programs in Beijing; 2.possessing normal reading and writing abilities to complete the questionnaire independently; 3.having signed an informed consent form, willing to participate and able to cooperate actively. |
||||||||||||||||||||||
|
排除标准: |
1.生物类和医学类专业学生; 2.正在参加或者近3个月参与过其他类似研究者; 3.自身合并有严重心、脑、肾、眼或神经系统疾病而无力阅读和填写者; 4.无法与人正常沟通交流者; 5.在研究过程中,患者因其他原因主动要求推出研究; 6.心理问题严重,需要心理医生进行干预和治疗者; 7.自身的某些基础疾病病情恶化不能继续参与研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Students specialising in biological or medical disciplines; 2. Individuals currently participating in, or having participated in similar studies within the past three months; 3. Those with severe concomitant cardiac, cerebral, renal, ocular, or neurological conditions rendering them incapable of reading and completing the forms; 4. Individuals unable to communicate effectively with others; 5. Patients who voluntarily withdraw from the study during its course for other reasons; 6. Individuals with severe psychological issues requiring intervention and treatment by a psychiatrist; 7. Participants whose underlying medical conditions deteriorate to the extent that continued study participation is no longer feasible. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-01 00:00:00至 To 2026-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-12-01 00:00:00 至 To 2026-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在随机分组之前,参与者被告知他们将被分配到为期 3 周的干预组或候补名单对照组。 使用 Excel 2016 将受试者随机分配到组中。在单元格“A”中,输入单词“Number”,后跟数字 1 到 146。在单元格 'B' 中,输入了 'Random Number',并使用随机数生成公式 RANDBETWEEN(1,146) 生成了 146 个随机数,然后固定了这些随机数。在单元格 'C' 中,输入了 'Group',干预组为奇数,对照组为偶数。这项研究对受试者不知情;他们在被纳入时被单独沟通,只被告知要完成的任务,而不透露他们的小组状态。此外,Web 平台使用帐户密码和 IP 登录限制进行保护,以防止组之间的交叉污染。 参与者将被随机分配到干预组或对照组。在整个干预过程中,干预组和对照组的参与者将被禁止相互交流。他们将被放置在不同的聊天组中,并且不会被告知他们是属于干预组还是对照组。这样可确保参与者不知道他们的组分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Before randomization, participants were notified that they would be allocated to either a 3-week intervention group or a waitlist control group. The subjects were randomly assigned into groups using Excel 2016. In cell ‘A’, the word ‘Number’ was entered, followed by numbers 1 to 146. In cell ‘B’, ‘Random Number’ was entered, and the random number generation formula: RANDBETWEEN(1,146) was used to generate 146 random numbers, which were then fixed. In cell ‘C’, ‘Group’ was entered, with odd numbers designated for the intervention group and even numbers for the control group. This study was blinded to the subjects; they were individually communicated with upon inclusion, only informed about the tasks to be completed, without disclosure of their group status. Additionally, the web platform was secured with account passwords and IP login restrictions to prevent cross-contamination between groups. Participants will be randomly assigned to either the intervention group or the control group. Throughout the entire intervention process, participants in the intervention group and the control group will be prohibited from communicating with each other. They will be placed in different chat groups and will not be informed whether they belong to the intervention group or the control group. This measure ensures that participants do not know their group assignment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
数据分析者和结果评估者 |
|
Blinding: |
Outcome assessors and data analysts were blinded to group allocation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
开放科学平台(https://osf.io/dashboard) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open Science Framework(https://osf.io/dashboard) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
在所抽取的学校、院系中招募参加实验的志愿者,分发问卷(附件4),对其HIV/AIDS的知识水平进行测定。根据其得分情况,纳入在基线范围内的志愿者。 在实验开展前,研究者向志愿者表明来意解释调查的目的和步骤,承诺匿名和保密,取得志愿者的信任与配合,签署知情同意书;并耐心解答他提出的问题和疑问。 在平台验证阶段,研究者指导研究对象使用平台。在其使用平台过程中,由平台的后台记录并保存研究对象的研究资料。在研究结束后,对所收集到的资料进行分析。 采用Epidata 3.1建立数据库,双人录入数据并核对 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected from volunteers recruited from selected universities and departments. Participants completed a baseline knowledge questionnaire on HIV/AIDS (Appendix 4), and those within the target range were enrolled. Prior to the intervention, researchers explained the study purpose and procedures to participants, ensured confidentiality and anonymity, and obtained written informed consent. Throughout the intervention, participant interactions with the platform were automatically recorded and stored via the platform’s backend system. After the intervention concluded, the data were retrieved for analysis. A dedicated database was established using Epidata 3.1, and double data entry with cross-checking was conducted to ensure accuracy. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |